Class Actions
Navan, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that Navan, Inc. (NAVN) Misled Investors in Connection to its IPO
February 24, 2026
Diego Lefebre
Search
Categories
Archives
Recent Posts
Investment Monitoring From Robbins LLP
To ensure your financial investments are being managed honestly, enroll in Stock Watch, our free investment monitoring service for individual and institutional investors.
Class Actions
Corcept Therapeutics Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that Corcept Therapeutics Incorporated (CORT) Misled Investors Regarding the Viability of its New Product Candidate
February 20, 2026
Class Actions
PayPal Holdings, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that PayPal Holdings, Inc. (PYPL) Misled Investors Regarding its Branded Checkout Offerings
February 17, 2026
Class Actions
Enphase Energy, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that Enphase Energy, Inc. (ENPH) Misled Investors Regarding its Ability to Manage its Channel Inventory
February 17, 2026
Class Actions
REGENXBIO, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that REGENXBIO, Inc. (RGNX) Misled Investors Regarding the Viability of its Drug Candidate RGX-111
February 16, 2026
Class Actions
Kyndryl Holdings, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that Kyndryl Holdings, Inc. (KD) Materially Misstated its Financial Statements
February 11, 2026
Class Actions
uniQure N.V. Class Action Lawsuit
Robbins LLP is Investigating Allegations that uniQure (QURE) Misled Investors Regarding the Likelihood of FDA Approval of its Leading Drug Candidate, AMT-130
February 10, 2026
Class Actions
POMDoctor Ltd. Class Action Lawsuit
Robbins LLP is Investigating Allegations that POMDoctor Ltd. (POM) was the Subject of a Pump-and-Dump Scheme
February 9, 2026
Class Actions
Inovio Pharmaceuticals, Inc. Class Action Lawsuit
Robbins LLP is Investigating Allegations that Inovio Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA Device
February 9, 2026
Protect your